Susquehanna Portfolio Strategies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,486	Closed	-$724K	–	855
2025 Q1	$724K	Buy	+5,486	New	+$684K	0.31%	61

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna Portfolio Strategies's ITCI Position: Q2 2025 in Review

Susquehanna Portfolio Strategies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,486 shares — an estimated $724K sold.

Susquehanna Portfolio Strategies first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $724K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Susquehanna Portfolio Strategies reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Susquehanna Portfolio Strategies sold 5,486 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $724K.
Susquehanna Portfolio Strategies first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Susquehanna Portfolio Strategies's Intra-Cellular Therapies Inc. position peaked at $724K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.